Clinical trials
Heart Failure NYHA Class III clinical trials
Below are recruiting heart failure nyha class iii clinical trials, each written for real people, not researchers. We’re tracking 130 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05793996RecruitingPhase 4
Testing an iron infusion for iron deficiency in HFpEF
This study checks how common iron deficiency is in people with HFpEF (heart failure with preserved pumping strength) and tests whether an iron infusion (Ferinject®) improves health. It targets people with stable heart symptoms and lab results showing low iron stores or related iron deficiency.
TomskAges 18 years+ - NCT05685303Recruiting
Testing a treatment for heart failure symptoms with normal pumping ability
This study is looking at a new treatment for people with heart failure where the heart’s pumping strength is not reduced much (HFpEF or HFmrEF), but pressure inside the heart is high during exercise. It may help relieve symptoms in people who still feel unwell during normal activity despite stable standard treatment.
Phoenix, ArizonaAges 40 years+ - NCT05373940Recruiting
ICD placement to prevent sudden heart death in people over 70
This study looks at placing an ICD, a device that can stop dangerous heart rhythms, to help prevent sudden cardiac death. It is for people over 70 with specific heart function and heart failure symptoms.
Aix-en-ProvenceAges 70 years+ - NCT05279742Enrolling by invitationPhase 1/Phase 2
Study drug to boost a hormone system in HFpEF
This early-phase trial tests a treatment that aims to improve the “natriuretic peptide” hormone system in people with HFpEF (heart failure with preserved pumping strength). It may help reduce symptoms and improve heart and fluid pressure behavior, especially in certain related conditions like kidney disease.
Rochester, MinnesotaAges 18 years+ - NCT05230745Recruiting
Test device for heart failure safety and how well it works
This trial studies whether the ContraBand device can be safely placed in people with long-term, symptomatic heart failure and reduced heart pumping. It also looks at whether the approach is practical and tolerable, and gathers early safety information.
AalstAges 18–85 - NCT05138575RecruitingPhase 2
Testing SGLT2 pill and potassium nitrate for heart failure with preserved EF
This trial studies whether two medicines—an SGLT2 inhibitor and potassium nitrate—can improve symptoms and heart function in people with heart failure with preserved ejection fraction (HFpEF). It focuses on people who still have signs of “stiff” or high filling pressure in the heart despite a normal-ish ejection fraction.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05057806RecruitingEarly Phase 1
Testing how ketones may affect heart benefits in type 2 diabetes
This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.
San Antonio, TexasAges 18–80 - NCT04913805RecruitingPhase 2
Study for HFpEF using heart pressure and energy signals
This Phase 2 study tests how matching heart “filling pressure” and heart muscle “energy use” may improve understanding or treatment of HFpEF, a type of heart failure with preserved pumping strength. You may be asked to have heart scans/tests and follow a study plan if your symptoms and test results fit.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04592445Recruiting
Nerve ablation for right-sided symptoms in HFpEF heart failure
This trial tests a procedure to “turn off” the right greater splanchnic nerve to improve symptoms in people with HFpEF (heart failure with preserved pumping function). If successful, it may reduce shortness of breath and fluid congestion in daily life.
Birmingham, AlabamaAges 40 years+ - NCT04419480Recruiting
Monitoring to help prevent complications after cardiogenic shock
This study tests a special monitoring approach (likely using an implanted device) to help prevent serious complications after you survive cardiogenic shock in the hospital. It may help the care team detect problems earlier so treatments can start sooner.
Falls Church, VirginiaAges 18 years+
Hear when a new Heart Failure NYHA Class III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for heart failure nyha class iii?
- Yes. Clin2 currently lists 130 recruiting heart failure nyha class iii studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a heart failure nyha class iii trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a heart failure nyha class iii trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.